Home・Aandelen Lijst・BioNTech SE ADR

BioNTech SE ADR

Gesloten

SectorGezondheidszorg

90.78 -1.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

88.01

Max

93.55

Belangrijke statistieken
By Trading Economics
Inkomsten	-239M -541M
Verkoop	-779M 120M
EPS	-1.95
Winstmarge	-450.381
Werknemers	7,807
EBITDA	-383M -450M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+36.04% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.8B 23B
Vorige openingsprijs	91.92
Vorige sluitingsprijs	90.78

BioNTech SE ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2026, 20:03 UTC

News

Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3 aug 2026, 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31 jul 2026, 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30 jul 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29 jul 2026, 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28 jul 2026, 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27 jul 2026, 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24 jul 2026, 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 jul 2026, 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 jul 2026, 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 jul 2026, 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Peer Vergelijking

Prijswijziging

BioNTech SE ADR Prognose

Koersdoel

By TipRanks

36.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 125.5 USD 36.04%

Hoogste 158 USD

Laagste 94 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioNTech SE ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan BioNTech SE ADR - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac